06 Hexavalent Investment Case pdf
gavi.org
HEXAVALENT INVESTMENT
CASE
BOARD MEETING
Aur?lia Nguyen, Kate O?Brien
26 -27 June 2023, Geneva, Switzerland
Governance pathway and key decisions
Board approved:
? In -principle support for wP -Hexavalent , subject to a vaccine being licensed, recommended for use by WHO, WHO
prequalified, and with market attributes met that support the successful implementation
? Support for IPV -based on the rationale that polio eradication is a global public health good, and routine vaccination
with IPV plays a fundamental role in the polio eradication strategy
Gavi Alliance partners assessed Hexavalent support conditions , using price and supply information ? 4/5 conditions met,
price condition to be confirmed by MSDC
MSDC (February 2023) confirmed that the price aligns with Hexavalent?s expected benefits ? 5/5 support conditions are met
PPC (May 2023) recommended to the Board to open a funding window for Hexavalent in Q3 2023
Board (June 2023) to decide on opening a funding window for Hexavalent in Q3 2023
2018
2022
2023
2019
Gavi joined GPEI as an official core partner
Board approved : continuation of its 2019 IPV support decision -countries are exempt from Gavi eligibility and co -financing
policies until polio eradication and the withdrawal of bivalent oral polio vaccine (bOPV ) from routine immunisation
Board Meeting, 26 -27 June 2023 2